$MHTX
MANHATTAN SCIENTIFICS INC

2023 Q4 Form 10-Q Financial Statement

#000147793223008674 Filed on November 20, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $9.000K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $149.0K $180.0K $175.0K
YoY Change -12.35% 2.86% 0.0%
% of Gross Profit
Research & Development $2.000K $3.000K $2.000K
YoY Change -50.0% 50.0% -33.33%
% of Gross Profit
Depreciation & Amortization $1.000K $0.00 $0.00
YoY Change 0.0% -100.0%
% of Gross Profit
Operating Expenses $151.0K $180.0K $2.000K
YoY Change -13.22% 8900.0% -33.33%
Operating Profit -$180.0K -$168.0K
YoY Change 7.14% -5.62%
Interest Expense -$103.0K $0.00 $7.000K
YoY Change -53.6% -100.0% 0.0%
% of Operating Profit
Other Income/Expense, Net -$82.00K $97.00K
YoY Change -184.54% -109.92%
Pretax Income -$254.0K -$260.0K -$71.00K
YoY Change -35.86% 266.2% -93.86%
Income Tax
% Of Pretax Income
Net Earnings -$254.0K -$262.0K -$71.00K
YoY Change -35.86% 269.01% -93.86%
Net Earnings / Revenue -788.89%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 559.3M shares 559.3M shares 559.3M shares
Diluted Shares Outstanding 559.3M shares 559.3M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.00K $90.00K $288.0K
YoY Change -61.71% -68.75% -21.31%
Cash & Equivalents $67.00K $89.00K $288.0K
Short-Term Investments
Other Short-Term Assets $2.000K $0.00 $8.000K
YoY Change -85.71% -100.0% 14.29%
Inventory
Prepaid Expenses $2.000K $1.000K $8.000K
Receivables
Other Receivables
Total Short-Term Assets $69.00K $90.00K $296.0K
YoY Change -63.49% -69.59% -56.02%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $2.000K
YoY Change -100.0% -100.0% -60.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $245.0K $340.0K $1.064M
YoY Change -70.8% -68.05% -62.08%
Other Assets $2.000K $0.00 $2.000K
YoY Change 0.0% -100.0% 0.0%
Total Long-Term Assets $247.0K $342.0K $1.068M
YoY Change -70.67% -67.98% -62.03%
TOTAL ASSETS
Total Short-Term Assets $69.00K $90.00K $296.0K
Total Long-Term Assets $247.0K $342.0K $1.068M
Total Assets $316.0K $432.0K $1.364M
YoY Change -69.35% -68.33% -60.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $133.0K $130.0K $115.0K
YoY Change 11.76% 13.04% -25.32%
Accrued Expenses $1.915M $1.782M $1.351M
YoY Change 33.08% 31.9% 24.98%
Deferred Revenue
YoY Change
Short-Term Debt $60.00K $60.00K $139.0K
YoY Change -45.45% -56.83%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.118M $1.980M $1.605M
YoY Change 26.98% 23.36% 29.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.118M $1.980M $1.605M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.118M $1.980M $1.605M
YoY Change 26.98% 23.36% 18.1%
SHAREHOLDERS EQUITY
Retained Earnings -$72.42M -$72.16M -$70.85M
YoY Change 1.64% 1.84% 3.46%
Common Stock $559.0K $559.0K $559.0K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.802M -$2.606M -$1.299M
YoY Change
Total Liabilities & Shareholders Equity $316.0K $432.0K $1.364M
YoY Change -69.35% -68.33% -60.87%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$254.0K -$262.0K -$71.00K
YoY Change -35.86% 269.01% -93.86%
Depreciation, Depletion And Amortization $1.000K $0.00 $0.00
YoY Change 0.0% -100.0%
Cash From Operating Activities -$10.00K -$40.00K -$88.00K
YoY Change -88.51% -54.55% -1.12%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$8.000K $80.00K $0.00
YoY Change -300.0%
Cash From Investing Activities -$8.000K $80.00K $0.00
YoY Change -300.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -10.00K -10.00K
YoY Change -100.0% 0.0%
NET CHANGE
Cash From Operating Activities -10.00K -40.00K -88.00K
Cash From Investing Activities -8.000K 80.00K 0.000
Cash From Financing Activities 0.000 -10.00K -10.00K
Net Change In Cash -18.00K 30.00K -98.00K
YoY Change -84.07% -130.61% 13.95%
FREE CASH FLOW
Cash From Operating Activities -$10.00K -$40.00K -$88.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001099132
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
559281064 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
559281064 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
MANHATTAN SCIENTIFICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity File Number
EntityFileNumber
000-28411
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0460639
dei Entity Address Address Line1
EntityAddressAddressLine1
244 Fifth Ave
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2341
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
541-2405
dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
559281064 shares
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
175000 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
14000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
90000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
189000 usd
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
340000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
839000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1000 usd
CY2023Q3 us-gaap Other Assets
OtherAssets
2000 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
2000 usd
CY2023Q3 us-gaap Assets
Assets
432000 usd
CY2022Q4 us-gaap Assets
Assets
1031000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
128000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
119000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1782000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1439000 usd
CY2023Q3 us-gaap Deferred Revenue
DeferredRevenue
10000 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
0 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
60000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
110000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1980000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1668000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1980000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1668000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q3 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
1058000 usd
CY2022Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
1058000 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
559000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
559000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
68996000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
68996000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72161000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71250000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2606000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1695000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
432000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1031000 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap Revenues
Revenues
9000 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
50000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
177000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
175000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
544000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
548000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
180000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
177000 usd
us-gaap Operating Expenses
OperatingExpenses
552000 usd
us-gaap Operating Expenses
OperatingExpenses
555000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-180000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-168000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-552000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-505000 usd
CY2023Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
-82000 usd
CY2022Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
104000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-374000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-1809000 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
15000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
0 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
7000 usd
us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
20000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-82000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
97000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-359000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1829000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-262000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-71000 usd
us-gaap Net Income Loss
NetIncomeLoss
-911000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2334000 usd
CY2023Q3 mhtx Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
559281064 shares
CY2022Q3 mhtx Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
559281064 shares
mhtx Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
559281064 shares
mhtx Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
559281064 shares
CY2023Q3 mhtx Basic And Diluted Loss Per Common Share Basic And Diluted
BasicAndDilutedLossPerCommonShareBasicAndDiluted
-0.00
CY2022Q3 mhtx Basic And Diluted Loss Per Common Share Basic And Diluted
BasicAndDilutedLossPerCommonShareBasicAndDiluted
-0.00
mhtx Basic And Diluted Loss Per Common Share Basic And Diluted
BasicAndDilutedLossPerCommonShareBasicAndDiluted
-0.00
mhtx Basic And Diluted Loss Per Common Share Basic And Diluted
BasicAndDilutedLossPerCommonShareBasicAndDiluted
-0.00
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1695000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-420000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2115000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-229000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2344000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-262000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2606000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1035000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-647000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
388000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1616000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1228000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-71000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1299000 usd
us-gaap Net Income Loss
NetIncomeLoss
-911000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2334000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-374000 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-1809000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
19000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
15000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-13000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
343000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
222000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-176000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-262000 usd
mhtx Proceeds From Sale Of Assets Held For Sale
ProceedsFromSaleOfAssetsHeldForSale
0 usd
mhtx Proceeds From Sale Of Assets Held For Sale
ProceedsFromSaleOfAssetsHeldForSale
300000 usd
us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
110000 usd
us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
28000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
110000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
328000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
20000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-20000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-10000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-86000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
56000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
175000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
232000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
288000 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
mhtx Investment In Equity Shares Transferred To Pay Note Down
InvestmentInEquitySharesTransferredToPayNoteDown
30000 usd
mhtx Investment In Equity Shares Transferred To Pay Note Down
InvestmentInEquitySharesTransferredToPayNoteDown
0 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
559281064 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72161000 usd
CY2023Q3 mhtx Working Capital
WorkingCapital
-1890000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.</p>
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
0 usd
mhtx Common Stock Owned Share
CommonStockOwnedShare
40466501 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Deferred Revenue
DeferredRevenue
10000 usd
CY2023Q3 us-gaap Investments
Investments
340000 usd
CY2022Q4 us-gaap Investments
Investments
839000 usd
us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
28922917 shares
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
28922917 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-262000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-71000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
559281064 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
559281064 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Net Income Loss
NetIncomeLoss
-911000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2334000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
559281064 shares
CY2022Q4 us-gaap Investments
Investments
839000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-374000 usd
mhtx Sale Of Investment Securities
SaleOfInvestmentSecurities
-110000 usd
us-gaap Debt Securities Held To Maturity Transfer Amount
DebtSecuritiesHeldToMaturityTransferAmount
15000 usd
CY2023Q3 us-gaap Investments
Investments
340000 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
mhtx Royalty Percentage On Dental Products
RoyaltyPercentageOnDentalProducts
0.10 pure
mhtx Royalty Percentage On Other Licensed Products
RoyaltyPercentageOnOtherLicensedProducts
0.05 pure
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1782000 usd

Files In Submission

Name View Source Status
0001477932-23-008674-index-headers.html Edgar Link pending
0001477932-23-008674-index.html Edgar Link pending
0001477932-23-008674.txt Edgar Link pending
0001477932-23-008674-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mhtx-20230930.xsd Edgar Link pending
mhtx_10q.htm Edgar Link pending
mhtx_ex311.htm Edgar Link pending
mhtx_ex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mhtx-20230930_cal.xml Edgar Link unprocessable
mhtx-20230930_lab.xml Edgar Link unprocessable
mhtx-20230930_def.xml Edgar Link unprocessable
mhtx-20230930_pre.xml Edgar Link unprocessable
mhtx_10q_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending